Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.67
-0.015-0.41%
Last update: Oct 14, 3:09 PM
Fulcrum Therapeutics Inc (FULC) Stock Price, Quote, News & History
FULCNASDAQ
| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF)...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Fulcrum Therapeutics (NASDAQ:FULC) through any online brokerage.
Other companies in Fulcrum Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Fulcrum Therapeutics has a consensus price target of $8.00.
The stock price for Fulcrum Therapeutics (NASDAQ: FULC) is $3.665 last updated October 14, 2026 at 3:09 PM EDT.
There are no upcoming dividends for Fulcrum Therapeutics.
Fulcrum Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Fulcrum Therapeutics.
Fulcrum Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
